Unlocking new potential in cannabinoids.
Cultured ingredients offer a more accessible and sustainable way to produce an array of important products across industries. In our landmark partnership with Cronos Group, we are working to produce pure cultured cannabinoids at industrial scale.
The Cannabis Industry
Predicted value by 2030
THC and CBD in the current cannabinoid market
Cannabis is a rapidly growing industry, predicted to reach over $100 billion worldwide by 2030. The cannabis plant produces hundreds of different cannabinoids with a range of potential pharmaceutical applications. The most highly concentrated of these compounds are THC and CBD; other molecules such as CBC, CBG, and THCV are present only in minute quantities, making them impractical to extract and purify. While the first two compounds currently constitute over 80% of the current cannabinoid market, rare cannabinoid variants are a significant new market opportunity if they can be produced in pure form at scale—with uses ranging from antioxidants to therapeutics.
Our project with Cronos is focused on building strains that produce eight target cannabinoids at high quality and purity. We do this by transferring the DNA sequences for cannabinoid production into organisms like yeast and E. coli and then using our Foundry including our high-throughput fermentation capabilities. The cultured cannabinoids are identical to those extracted from the plant using traditional methods. By tapping into the power of biological manufacturing, we can access medically important cannabinoids at scale and produce them reliably.
Cronos Group, a vertically integrated cannabis company, has gathered extensive data on the full spectrum of cannabinoids and their properties to determine the best molecular pathways for synthesizing them. To scale manufacturing of products from this partnership, Cronos has purchased an 84,000 square foot fermentation facility in Winnipeg, Canada. We’re thrilled to be working with Cronos as they build the world’s most innovative cannabinoid platform.
What We’ve Accomplished
To date, we have run 8 million tests of more than 10,000 engineered strains, leveraging 30,000 different gene constructs—all in the course of just two years. These efforts yielded several strains with industry-relevant titers for multiple rare cannabinoid compounds, the first of which is beginning commercial scale production.
Plants like cannabis hold many unique compounds that can have important health benefits. With synthetic biology and fermentation, those rare products can be made accessible at a commercial scale.
For more information, visit thecronosgroup.com.
- Engineered strains
- Tests run over 2 years
- Different gene constructs